111 Capital Trims Holdings in Amgen Inc. $AMGN

111 Capital reduced its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 25.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 5,090 shares of the medical research company’s stock after selling 1,753 shares during the period. 111 Capital’s holdings in Amgen were worth $1,666,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Lowe Brockenbrough & Co. Inc. boosted its stake in shares of Amgen by 0.4% during the 4th quarter. Lowe Brockenbrough & Co. Inc. now owns 27,261 shares of the medical research company’s stock valued at $8,923,000 after buying an additional 116 shares during the last quarter. Peachtree Investment Partners LLC purchased a new position in shares of Amgen during the 4th quarter valued at approximately $207,000. MCF Advisors LLC boosted its stake in shares of Amgen by 48.6% during the 4th quarter. MCF Advisors LLC now owns 10,468 shares of the medical research company’s stock valued at $3,426,000 after buying an additional 3,424 shares during the last quarter. Closed End Fund Advisors Inc. purchased a new position in shares of Amgen during the 4th quarter valued at approximately $262,000. Finally, First Command Advisory Services Inc. boosted its stake in shares of Amgen by 5.8% during the 4th quarter. First Command Advisory Services Inc. now owns 2,151 shares of the medical research company’s stock valued at $704,000 after buying an additional 118 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on AMGN shares. Argus reduced their target price on Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research note on Wednesday, May 20th. Mizuho upped their price target on Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Rothschild & Co Redburn upped their price target on Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research report on Wednesday, February 18th. Erste Group Bank reissued a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Finally, Wall Street Zen lowered Amgen from a “buy” rating to a “hold” rating in a research report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $353.81.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer, expanding a key oncology product into the European market and improving the drug’s commercial outlook. Article Title
• Positive Sentiment: Amgen also showed fresh momentum in autoimmune therapies, with new Phase 3 and real-world data on UPLIZNA and TAVNEOS presented at EULAR 2026, which supports the company’s growing presence in high-value specialty medicine niches. Article Title
• Positive Sentiment: One analyst note upgraded Amgen to a cautious Buy, citing improved fundamentals, a diversified pipeline, and growth drivers such as Imdelltra, Uplizna, Tepezza, and Repatha. Article Title

Amgen Price Performance

Shares of NASDAQ AMGN opened at $349.58 on Friday. Amgen Inc. has a 1-year low of $267.83 and a 1-year high of $391.29. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The business’s fifty day moving average price is $341.35 and its two-hundred day moving average price is $345.47. The firm has a market capitalization of $188.67 billion, a PE ratio of 24.33, a P/E/G ratio of 3.47 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same period last year, the company earned $4.90 earnings per share. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts expect that Amgen Inc. will post 22.38 EPS for the current year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.